TY - JOUR
T1 - Prolonged infusion of gemcitabine
T2 - Clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia
AU - Gandhi, Varsha
AU - Plunkett, William
AU - Du, Min
AU - Ayres, Mary
AU - Estey, Elihu H.
PY - 2002/2/1
Y1 - 2002/2/1
N2 - Purpose: To determine the maximum tolerated duration of infusions at the fixed gemcitabine dose rate of 10 mg/m2/min and to analyze the pharmacodynamic actions in leukemia blasts during gemcitabine therapy. Patients and Methods: The study was conducted in a phase I trial by escalating the duration of gemcitabine infusion at a fixed-dose rate of 10 mg/m2/min. Patients with relapsed or refractory acute myelogenous leukemia (AML) received gemcitabine for 8.0 (n = 3), 10.0 (n = 3), 12.5 (n = 8), 15.5 (n = 3), or 18.0 hours (n = 2). Pharmacokinetic and pharmacodynamic investigations were undertaken in circulating AML blasts. Results: Gemcitabine was infused for up to 18 hours at the fixed-dose rate. Four patients had grade 3 toxicities at longer infusion schedules. One patient had a partial remission; two others had a reduction in blasts and concomitant rise in neutrophils. Gemcitabine triphosphate was detectable in AML cells even at 1 hour after the start of infusion in eight patients. The concentration ranged from 130 to 900 μmol/L at the end of the infusion. Consistently, there was a rapid decline in DNA synthesis, which remained suppressed at 85% to 95% during and for at least 10 hours after the end of the infusion. Compared with levels in cells measured before therapy, at 8 hours after the start of the infusion, there was a decline in the cellular purine deoxynucleotide pools. Conclusion: At the fixed-dose rate of 10 mg/m2/ min, gemcitabine could be administered for longer than 12 hours without untoward toxicity. The favorable toxicity profile and pharmacokinetic and pharmacodynamic features warrant combination with DNA-damaging agents.
AB - Purpose: To determine the maximum tolerated duration of infusions at the fixed gemcitabine dose rate of 10 mg/m2/min and to analyze the pharmacodynamic actions in leukemia blasts during gemcitabine therapy. Patients and Methods: The study was conducted in a phase I trial by escalating the duration of gemcitabine infusion at a fixed-dose rate of 10 mg/m2/min. Patients with relapsed or refractory acute myelogenous leukemia (AML) received gemcitabine for 8.0 (n = 3), 10.0 (n = 3), 12.5 (n = 8), 15.5 (n = 3), or 18.0 hours (n = 2). Pharmacokinetic and pharmacodynamic investigations were undertaken in circulating AML blasts. Results: Gemcitabine was infused for up to 18 hours at the fixed-dose rate. Four patients had grade 3 toxicities at longer infusion schedules. One patient had a partial remission; two others had a reduction in blasts and concomitant rise in neutrophils. Gemcitabine triphosphate was detectable in AML cells even at 1 hour after the start of infusion in eight patients. The concentration ranged from 130 to 900 μmol/L at the end of the infusion. Consistently, there was a rapid decline in DNA synthesis, which remained suppressed at 85% to 95% during and for at least 10 hours after the end of the infusion. Compared with levels in cells measured before therapy, at 8 hours after the start of the infusion, there was a decline in the cellular purine deoxynucleotide pools. Conclusion: At the fixed-dose rate of 10 mg/m2/ min, gemcitabine could be administered for longer than 12 hours without untoward toxicity. The favorable toxicity profile and pharmacokinetic and pharmacodynamic features warrant combination with DNA-damaging agents.
UR - http://www.scopus.com/inward/record.url?scp=0036467995&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036467995&partnerID=8YFLogxK
U2 - 10.1200/JCO.20.3.665
DO - 10.1200/JCO.20.3.665
M3 - Article
C2 - 11821446
AN - SCOPUS:0036467995
SN - 0732-183X
VL - 20
SP - 665
EP - 673
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 3
ER -